Exploring the interaction of copper-esculetin complex with ct-DNA: Insight from spectroscopic and docking studies

Functionalization of Fe3O4/rGO magnetic nanoparticles with resveratrol and in vitro DNA interaction

Based on the previous research, we found that the magnetic nanocomposite Fe₃O₄/rGO (reduced graphene oxide) has a good drug loading effect. Therefore, in this paper, we studied the positive role of Fe₃O₄/rGO as a drug carrier in the interaction between resveratrol (RES) and calf-thymus DNA (ct-DNA). The fluorescence experiment is used to evaluate by the Stern-Volmer equation, the quenching constant of RES - ct-DNA system with and without Fe₃O₄/rGO decreases with the increasing temperature. It was found the quenching mode of RES - ct-DNA and Fe₃O₄/rGO - RES - ct-DNA systems were all static quenching, but the binding constant of RES -ct-DNA increased from 4.14 ± 0.21 × 10⁴ L mol^-1 to 10.12 ± 0.02 × 10⁴ L mol^-1. It was found that Fe₃O₄/rGO formed a ternary complex with RES and ct-DNA by ultraviolet spectrum (UV-vis), resonance light scattering experiments (RLS) and scanning electron microscope (SEM). Meanwhile, Fourier transform infrared (FT-IR) and circular dichroism (CD) experiments show that Fe₃O₄/rGO and Fe₃O₄/rGO loaded with RES have effect on the secondary structure of ct-DNA and change the conformation of ct-DNA. On the cellular level, the comet assay shows that Fe₃O₄/rGO and Fe₃O₄/rGO - RES could not cause DNA strand break to the mouse hepatocytes after 24 co-incubation. These results confirm that Fe₃O₄/rGO nanocomposites have good application potential, which can be used as a good drug carrier in a wide range of therapeutic methods.

Studies on the interaction between 3-biotinylate-6-benzimidazole B-nor-cholesterol analogs and ct-DNA

The interaction mechanism between 3-biotinylate-6-benzimidazole B-nor-cholesterol analogs and ct-DNA was studied under conditions similar to physiological. The interaction mechanism between ct-DNA and three different types of compounds was studied by spectroscopic...

Anticancer activity of pyrimidodiazepines based on 2-chloro-4-anilinoquinazoline: synthesis, DNA binding and molecular docking

Multidrug resistance to chemotherapy is a critical health problem associated with mutation of the therapeutic target. Therefore, the development of anticancer agents remains a challenge to overcome cancer cell resistance. Herein, a new series of quinazoline-based pyrimidodiazepines 16a-g were synthesized by the cyclocondensation reaction of 2-chloro-4-anilinoquinazoline-chalcones 14a-g with 2,4,5,6-tetraaminopyrimidine. All quinazoline derivatives 14a-g and 16a-g were selected by the U.S. National Cancer Institute (NCI) for testing their anticancer activity against 60 cancer cell lines of different panels of human tumors. Among the tested compounds, quinazoline-chalcone 14g displayed high antiproliferative activity with GI₅₀ values between 0.622-1.81 μM against K-562 (leukemia), RPMI-8226 (leukemia), HCT-116 (colon cancer) LOX IMVI (melanoma), and MCF7 (breast cancer) cancer cell lines. Additionally, the pyrimidodiazepines 16a and 16c exhibited high cytostatic (TGI) and cytotoxic activity (LC₅₀), where 16c showed high cytotoxic activity, which was 10.0-fold higher than the standard anticancer agent adriamycin/doxorubicin against ten cancer cell lines. COMPARE analysis revealed that 16c may possess a mechanism of action through DNA binding that is similar to that of CCNU (lomustine). DNA binding studies indicated that 14g and 16c interact with the calf thymus DNA by intercalation and groove binding, respectively. Compounds 14g, 16c and 16a displayed strong binding affinities to DNA, EGFR and VEGFR-2 receptors. None of the active compounds showed cytotoxicity against human red blood cells.

Antibacterial Activity of a Cationic Antimicrobial Peptide against Multidrug-Resistant Gram-Negative Clinical Isolates and Their Potential Molecular Targets

Antimicrobial resistance reduces the efficacy of antibiotics. Infections caused by multidrug-resistant (MDR), Gram-negative bacterial strains, such as Klebsiella pneumoniae (MDRKp) and Pseudomonas aeruginosa (MDRPa), are a serious threat to global health. However, cationic antimicrobial peptides (CAMPs) are promising as an alternative therapeutic strategy against MDR strains. In this study, the inhibitory activity of a cationic peptide, derived from cecropin D-like (ΔM2), against MDRKp and MDRPa clinical isolates, and its interaction with membrane models and bacterial genomic DNA were evaluated. In vitro antibacterial activity was determined using the broth microdilution test, whereas interactions with lipids and DNA were studied by differential scanning calorimetry and electronic absorption, respectively. A strong bactericidal effect of ΔM2 against MDR strains, with minimal inhibitory concentration (MIC) and minimal bactericidal concentrations (MBC) between 4 and 16 μg/mL, was observed. The peptide had a pronounced effect on the thermotropic behavior of the 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC)/1,2-dimyristoyl-sn-glycero-3-phosphorylglycerol (DMPG) membrane models that mimic bacterial membranes. Finally, the interaction between the peptide and genomic DNA (gDNA) showed a hyperchromic effect, which indicates that ΔM2 can denature bacterial DNA strands via the grooves.